Results 151 to 160 of about 5,996,360 (285)

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Determinants of the Cost of Illness in Iranian Prostate Cancer Patients. [PDF]

Prostate Cancer
Ravangard R, Keshavarz K, Seif M, Zeighami S, Jafari A, Jalali FS.   +5 more
europepmc   +1 more source

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source

NUDT21 Drives T‐Cell Acute Lymphoblastic Leukemia Through Dual Regulation of Alternative Polyadenylation and Transcriptional Activation

Advanced Science, EarlyView.
In summary, our study defines a coordinated oncogenic model in which NUDT21 integrates alternative polyadenylation–dependent UBE2D3 stabilization and transcriptional activation to sustain MYC‐driven T‐ALL cell survival, thereby establishing NUDT21 as a central regulatory node and a promising therapeutic target.
Conglian Qiu, Jianwei Wang, Zhiheng Li, Qi Ji, Hui Zhang, Qinyi Zhang, Senlin Zhang, Juanjuan Yu, Yanfang Tao, Yijun Wu, Chunxia Shi, Zong Zai, Zimu Zhang, Yizhen Li, Zhenjiang Bai, Shaoyan Hu, Jian Pan, Yang Yang, Shuiyan Wu   +18 more
wiley   +1 more source

Prostate cancer: Improving lives by not "overtreating" patients. [PDF]

Cent European J Urol
Salagierski M, Szarek P, Tortyna M, Poźniak-Balicka R.   +3 more
europepmc   +1 more source

Prostate Cancer

Oncology Times, 2004
openaire   +2 more sources

Integrating Spatial Proteogenomics in Cancer Research

Advanced Science, EarlyView.
Xx xx. ABSTRACT Background: Spatial proteogenomics marks a paradigm shift in oncology by integrating molecular analysis with spatial information from both spatial proteomics and other data modalities (e.g., spatial transcriptomics), thereby unveiling tumor heterogeneity and dynamic changes in the microenvironment.
Yida Wang, Yang Wu, Feng Zhang, Parthiban Periasamy, Haiyue You, Denise Goh, Rachel Elizabeth Ann Fincham, Xin Ning, Danping Wu, Lu Liu, Ying Jiang, Zhiwen Qian, Joe Yeong, Yan Zhang   +13 more
wiley   +1 more source

Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer

New England Journal of Medicine, 2017
K. Fizazi, N. Tran, L. Fein, N. Matsubara, A. Rodríguez‐Antolín, B. Alekseev, M. Özgüroğlu, D. Ye, S. Feyerabend, A. Protheroe, P. De Porre, T. Kheoh, Y. Park, M. Todd, K. Chi   +14 more
semanticscholar   +1 more source

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

Advanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu, Lingyao Zeng, Xulin Gan, Yilin Zhou, Han Shen, Dan Wu, Xin Shou, Minmin Jiang, Liyun Shi   +8 more
wiley   +1 more source

Retraction: Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source